Mymetics Corp (MYMX)

[Work Harder]

INVESTORS

https://ventureincubator.ch/partners/

Portfolio

Current Healthcare

Kuros

https://ventureincubator.ch/portfolio/

Switzerland, 14 July 2020

iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has raised an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.

https://ventureincubator.ch/news/

Araris Biotech AG announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs).

https://ventureincubator.ch/araris-biotech-ag-closes-seed-financing-round-of-chf-2-5-million/

Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group (ASX: PGC), a leading provider of medical equipment, devices and consumables.

https://ventureincubator.ch/kuros-biosciences-signs-agreement-with-surgical-specialties-on-distribution-of-magnetos-in-australia-and-new-zealand/

https://www.mckinsey.com/ch/overview